A hyperbaric chamber includes a plurality of enclosure sections including a first union enclosure section that has a first top wall, a first bottom wall, a first sidewall having a first opening. a second sidewall having a second opening, a third sidewall having a third opening, and a fourth sidewall having a fourth opening. The first sidewall, the second sidewall, the third sidewall, and the fourth sidewall are connected to the first top wall and the first bottom wall to form an open enclosure. The first door section is connectable to the first opening of the first union enclosure section. The plurality of end enclosure sections is connectable directly or indirectly to each of the second opening, the third opening, and the fourth opening of the union enclosure section. Each enclosure section is connectable to another by disengagable connectors.

A formulation comprising platelet rich plasma (PRP) for treatment of patients who have experienced brain injury, consisting of: a mixture of human plasma composed of pluripotent adult stem cells comprising very small embryonic like stem cells from autologous plasma or allogeneic plasma, D5W, glutathione, methylcobalamin, and regular insulin. The formulation is infused directly adjacent to a patient's brain through the nostrils or nares of the nasal cavity. Treatment using the formulation may be supplemented with one or more therapies including hyperbaric oxygen therapy (HBOT), cranial osteopathic therapy, intravenous (IV) nutrition, electroencephalographic (EEG) biofeedback, low level laser therapy (LLLT), transcranial magnetic stimulation (TMS), additional PRP pluripotent adult stem cell treatments, and a ketogenic diet and medium-chain triglyceride (MCT) oil therapy.

The embodied invention is a pressure control system on a hyperbaric chamber where the pressure regulation is automatic, continuous, and independent of the flow curve of the air supply compressor. The chamber is continuously controlled by an air venting control valve with electronic control to provide tight control. The control is able to be programmed to provide a therapeutic, varying pressure for treatment.

A method for noninvasive treatment of diabetic retinopathy helps prevent and reverses diabetic retinopathy and other vascular retinopathies, such as diabetic macular edema for a patient. The method comprises administering at least 80 percent pure oxygen to a patient in an oxygen chamber or nasal cannula. The oxygen chamber includes light emitting diodes that emit a light having a wavelength between 630-700 nm wavelengths on the patient. The method also includes administering an anti-inflammatory agent; an anti-oxidant; at least one of the following: an amino acid, arginine, and citrulline; and an omega-3 fatty acids to the patient. In extreme cases of diabetic retinopathy, a cold laser therapy is also administered to the patient with a wavelength between 570 nanometers and 1000 nanometers. The combination of all the aforementioned treatment modalities and compositions that work to synergistically to achieve unexpected clinical results for prevention and reversal of diabetic retinopathy.

An oxygen distributor (1) positionable, in use, in a wound for supplying oxygen to the wound has an oxygen delivery area (17) for, in use, receiving a supply of oxygen. At least one tube (19A) extends from the oxygen delivery area, having a tube wall with an oxygen-permeable, liquid-impermeable section. Oxygen delivered to the oxygen delivery area can flow away from the oxygen delivery area along the, or each, tube.

The invention disclosed provides means of inhibiting, ameliorating, and/or treatment of rheumatoid arthritis through the use of Noble gas containing mixtures. In one embodiment, the invention provides means of reducing inflammation and immune associated pathology through administration of Noble gas mixtures. In one specific embodiment, Xenon gas is administered to a patient in need at concentrations and frequencies sufficient to inhibit inflammatory and autoimmune processes. In another embodiment Noble gas mixtures are administered to reduce pain and provide symptomatic relieve to a patient suffering from rheumatoid arthritis. In another embodiment the use of Noble gas containing mixtures is disclosed as a means of reducing joint destruction through inhibition of matrix metalloprotease production and activity.

The present invention provides systems, methods, and apparatus for applying a hyperoxic therapy delivery system to a patient; administering hyperoxic gas to the patient according to an oxygen dose-response model; and adjusting the administration of the hyperoxic gas to the patient based upon monitored parameters related to a condition of the patient. Numerous additional features are disclosed.

Hyperbaric oxygen therapy (HBOT) settings of gas mixture and pressure are established based on electroencephalography (EEG) readings from a human within a hyperbaric chamber. Specifically, brainwave readings are affected by the HBOT process, which are used to improve the medical benefits achieved through the HBOT therapy regime, especially for treatments of cognitive disorders and neurological conditions detectable via EEG. In embodiments, HBOT settings are altered until a treated human is placed in a healing state, where cognition is enhanced. This healing state is quantitively definable through analysis of Alpha, Beta, Delta, and Theta EEG readings taken while in chamber and while outside the chamber. Once settings are determined to achieve a healing state of positive cognition, HBOT sessions can be conducted at pressure and gas mixture settings to ensure the healing state is achieved for each session. Post treatment analysis can be performed to determine EEG quantifiable improvements achieved.

An oxygen distributor (1) positionable, in use, in a wound for supplying oxygen to the wound has an oxygen delivery area (17) for, in use, receiving a supply of oxygen. At least one tube (19A) extends from the oxygen delivery area, having a tube wall with an oxygen-permeable, liquid-impermeable section. Oxygen delivered to the oxygen delivery area can flow away from the oxygen delivery area along the, or each, tube.

A system and method are provided for performing hyperbaric oxygen therapy treatment to stop a cascading effect of an inflammatory response to an injury. Hyperbaric oxygen therapy is performed during the inflammation to suppress the release of cytokines, most preferably, within 72 hours of sustaining the injury. Subject to evaluation of the patient, at least a second hyperbaric oxygen therapy treatment is performed.